Insider buying last 90 days
No open-market insider purchases were filed for AGL in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every AGL insider filing, plotted on the chart in Gekko.Open AGL in Gekko
NYSE: AGL
agilon health (AGL) Stock Analysis & Forecast
Oct 12 close
$85.49+3.10 (+3.8%)
Gekko Brief
AI summaryOct 12 closeThis week's commentary around agilon health centers on analyst sentiment and the upcoming earnings date rather than new operating news. Bernstein's Lance Wilkes reaffirmed a Buy rating on AGL.US with a target price of $125, while the company confirmed it will report third-quarter 2026 results after market close on 4 November, with a conference call at 4:30 p.m. ET. Other coverage this week placed AGL alongside peers such as INVO Fertility and CRISPR Therapeutics in broader sector comparisons.
AGL closed at $85.49, up 3.8%, sitting below its 50-day average of $89.30 but well above its 200-day average of $60.20. The GekkoIndex reads 60.8, placing the stock in the Accumulation zone, down 1.5 over five sessions. Shares trade 14.5% below the Gekko Fair Value estimate of $99.98. Over the past month the stock is down 4.8%, though it remains sharply higher over six months and one year.
The next earnings report falls on 4 November, 22 days out, inside a typical 20-trading-day holding period; the prior report produced an 8.4% reaction despite earnings per share of $1.04 versus an estimate of $0.14. No insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows, though one trailblazer holder is noted. Seasonality over five years shows the next 20 trading days averaging -14.9%, positive in only 1 of those years. Analyst consensus across 12 firms includes 3 buy, 8 hold and 1 sell ratings, with a consensus target of $115.83.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
agilon health price vs fair value
Close $85.49200-day averageGekko Fair Value $99.98
agilon health quick facts
- Market cap
- $1.43B
- P/E ratio
- —
- Forward P/E
- 178.6
- EPS, TTM
- −$15.41
- Revenue, TTM
- $5.92B
- Profit margin
- -3.9%
- Dividend yield
- —
- Beta
- 3.00
- Volume
- 158,666 avg 238,407
- 1-year return
- +235.3%
- Typical daily move
- ±6.2%
- Typical 20-day move
- ±15.4%
- 50-day average
- $89.30
- 200-day average
- $60.20
- Next earnings
- Nov 4 after close
- Shares outstanding
- 16.79M
agilon health swing-trade checklist
agilon health scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendmixed
Averages disagree
Close $85.49 sits between the 50-day ($89.30) and 200-day ($60.20) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
60.8, Accumulation
Reading 60.8 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
14.5% below
Price is 14.5% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−14.9% on average
From this point in the calendar, the next 20 trading days averaged −14.9% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
agilon health stock chart and price history
agilon health closed at $85.49 on Oct 12, 2026, +235.3% over the past year, inside a 52-week range of $7.48 to $133.04.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −4.8%
- 3 months
- −30.3%
- 6 months
- +295.2%
- 1 year
- +235.3%
The full AGL chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open AGL in Gekko
Follow agilon health through every session
Put AGL on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track AGL in GekkoFree for 7 days. No credit card required.
About agilon health
agilon health works with local primary care doctors across the United States to support care for older adults. Its model centers on helping these community-based physicians manage health services for senior patients, and the company has become associated with this approach to coordinating elder care at the primary care level.
The business serves seniors through two main groups: those enrolled in Medicare Advantage plans and those receiving traditional Medicare fee-for-service benefits. As of the end of 2021, agilon health reported serving roughly 238,000 senior clients in total, with the majority, about 186,300, covered under Medicare Advantage arrangements and the remainder, around 51,700, under fee-for-service Medicare.
The company began operations in 2016 under the name Agilon Health Topco, Inc. before adopting its present name, agilon health, inc., in March 2021. It is headquartered in Austin, Texas. Shares of the company are listed on the NYSE under the ticker AGL.
- Listed
- NYSE
- Sector
- Health services
- Industry
- Medical/Nursing services
- Website
- agilonhealth.com
agilon health GekkoIndex: the smart money zone
agilon health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60.8, in the Accumulation zone, down 1.5 points over five sessions.
60.8Accumulation
Down 1.5 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 84 | Not available | |||
| Accumulation (current zone) | 259 | −2.2% | −5.4% | ||
| Neutral | 217 | +4.6% | +14.6% | ||
| Distribution | 45 | Not available | |||
| Selling | 0 | Not available | |||
Average AGL share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the AGL price, zone by zone.Track AGL in Gekko
Is agilon health stock overvalued? Gekko Fair Value
agilon health trades 14.5% below Gekko Fair Value of $99.98, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what agilon health shares are worth, recalculated every trading day.
$99.98
Gekko Fair Value, Oct 10, 2026
14.5% Undervalued
At the end of Aug 2026 the price was 20.9% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open AGL in Gekko
agilon health insider and Congress trading
No open-market insider purchases were filed for agilon health, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in AGL were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for AGL, plotted on the chart in Gekko.Open AGL in Gekko
Buybacks
agilon health has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $35K
- As a share of market cap
- 0.00%
- Trailing four quarters
- $323K
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds AGL.
0added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
agilon health earnings: next date and track record
agilon health reports on Nov 4, 2026, after the close (23 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected after the close, 23 days away
- EPS estimate
- −$1.23
- Revenue estimate
- $1.46B
3 of 8reports beat the EPS estimate
±38.2%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- Agilon Health (AGL) exceeded Q2 2026 guidance across key financial metrics, driven by improved medical cost trends and strong Burden of Illness program performance. New CEO Tim O'Rourke, who joined in May, highlighted structural improvements in care delivery, AI-driven clinical tools, and deeper physician engagement. The company is seeing early signs of macro cost trend moderation combined with systematic clinical program execution.
- Guidance
- AGL raised full year 2026 guidance based on Q2 outperformance, improved medical cost trends first seen in Q1, and stronger-than-expected Burden of Illness program results. Management expressed confidence in long-term scalability and durability of the operating model.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $1.04 est $0.14 | $1.49B est $1.45B | −8.4% |
| May 6, 2026 | $1.80 est $1.13 | $1.42B est $1.38B | +126.9% |
| Feb 25, 2026 | −$11.50 est −$6.75 | $1.57B est $1.47B | +51.0% |
| Nov 4, 2025 | −$0.27 est −$0.18 | $1.44B est $1.42B | −7.0% |
| Aug 5, 2025 | −$6.25 est −$2.75 | $1.39B est $1.47B | −51.1% |
| May 6, 2025 | $0.03 est −$0.01 | $1.53B est $1.50B | −17.7% |
| Feb 25, 2025 | −$0.25 est −$0.18 | $1.52B est $1.52B | −7.7% |
| Nov 7, 2024 | −$0.29 est −$0.10 | $1.45B est $1.47B | −36.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
agilon health stock forecast and analyst price targets
Analysts’ average 12-month price target for agilon health is $115.83, +35.5% from the last close, from 12 firms rating the stock in the last 90 days.
$115.83consensus 12-month target, +35.5% from the last close
Now $85.49Avg $115.83
Low $85High $146
Each firm’s latest rating in the last 90 days: 12 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 5 | Bernstein | $125 | +46.2% |
| Sep 28 | Truist Financial | — | — |
| Sep 15 | Bernstein | $125 | +46.2% |
| Sep 9 | Bernstein | $86 | +0.6% |
| Sep 4 | Bernstein | $86 | +0.6% |
−5.4%average 20-day move after past Accumulation readings
−14.9%average move over the next 20 trading days in the last 5 years
±6.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
agilon health seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, agilon health averaged −14.9% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.2% | 4 of 5 |
| Next 10 trading days | −3.5% | 3 of 5 |
| Next 15 trading days | −8.5% | 1 of 5 |
| Next 20 trading days | −14.9% | 1 of 5 |
| Next 30 trading days | −29.8% | 0 of 5 |
For scale, AGL’s typical 20-trading-day move in either direction is about 15.4%.
agilon health market cap and key statistics
agilon health’s market cap is $1.43B and revenue of $5.92B over the last twelve months.
Valuation
- Market cap
- $1.43B
- Forward P/E
- 178.6
- EPS, TTM
- −$15.41
- Gekko Fair Value
- $99.98
Trading
- Volume
- 158,666
- Avg volume, 20 days
- 238,407
- 52-week high
- $133.04
- 52-week low
- $7.48
- Shares outstanding
- 16.79M
Financials
- Revenue, TTM
- $5.92B
- Profit margin
- -3.9%
- Return on equity
- -78.9%
- Quarterly earnings growth, YoY
- +301.0%
Risk and income
- Beta
- 3.00
- Typical daily move
- ±6.2%
- Typical 20-day move
- ±15.4%
agilon health stock news this week
Coverage of agilon health this week reads neutral: 1 positive, 2 neutral and 0 negative headlines.
- Head to Head Comparison: Agilon Health (NYSE:AGL) & INVO Fertility (NASDAQ:IVF)Defense World, Oct 11
- Is Agilon Health (AGL) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research, Oct 7
- Bernstein Maintains Agilon Health(AGL.US) With Buy Rating, Maintains Target Price $125Moomoo, Oct 6
- A 4:30 p.m. call will cover agilon health's third-quarter results on Nov. 4.Stock Titan, Oct 6
- agilon health Sets Date to Report Third Quarter 2026 Financial ResultsYahoo Finance, Oct 5
agilon health peers
agilon health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Neutral | 2.5% below |
| GHGuardant Health | Accumulation | 10.0% below |
| SOLVSolventum | Accumulation | 20.5% below |
| BTSGBrightSpring Health Services | Neutral | 2.8% above |
| EHCEncompass Health | Neutral | 7.3% above |
| DVADaVita | Neutral | 14.6% below |
A peer links to its own page where one exists.
agilon health stock FAQ
What is agilon health’s market cap?
agilon health’s market cap is $1.43B at the Oct 12, 2026 close of $85.49, with 16.79M shares outstanding.
What is the agilon health stock forecast?
The consensus analyst 12-month price target for agilon health is $115.83, +35.5% from the last close. Of the 12 firms that rated the stock in the last 90 days, 3 rate it a buy, 8 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is agilon health stock overvalued or undervalued?
On Gekko’s estimate agilon health is undervalued: the Oct 12, 2026 close of $85.49 is 14.5% below Gekko Fair Value of $99.98. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does agilon health report earnings next?
agilon health is expected to report on Nov 4, 2026, after the market closes (23 days away). Analysts expect earnings of −$1.23 per share on revenue of $1.46B. agilon health beat the earnings estimate in 3 of its last 8 reports, moving 38.2% on average across the report.
What is agilon health’s 52-week high and low?
agilon health’s 52-week high is $133.04 and its 52-week low is $7.48; it closed at $85.49 on Oct 12, 2026, +235.3% over the past year. Over the last five years the shares peaked at $736.00 on Mar 27, 2023.
Is agilon health stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and fair value), 1 as mixed (trend) and 2 as headwinds (earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See agilon health the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.